Cancer chemoprevention approaches generally use long-term, continuous treatment, which can lead to adverse events. This Opinion article discusses whether short-term, intermittent therapy that exploits synthetic lethal interactions in premalignant cells might reduce the toxicity of chemoprevention while retaining its benefits.
- Xiangwei Wu
- Scott M. Lippman